Sigma-1 and sigma-2 receptors are emerging therapeutic targets. We have identified that simple ammonium salts bind to these receptors and are effective in vivo. Radioligand binding assays were used to obtain structure-activity relationships of these salts. MTS assays were performed to determine their effect on growth in MCF7 and MDA-MB-486 cells. Anticancer properties were tested in NMRI mice transplanted with a fragment of mouse adenocarcinoma (MAC13). Antidepressant activity was tested using the forced-swim test and tail suspension tests. Dipentylammonium (K i 43 nM), tripentylammonium (K i 15 nM) and trihexylammonium (K i 9 nM) showed high affinity for the sigma-1 receptor. Dioctanoylammonium had the highest affinity (K 50 0.05 nM); this also showed the highest affinity for sigma-2 receptors (K i 13 nM). Dipentylammonium was found to have antidepressant activity in vivo. Branched-chain ammonium salts showed lower affinity. Bis(2-ethylhexyl)ammonium (K 50 29 µM), triisopentylammonium (K 50 196 µM) and dioctanoylammonium showed a low Hill slope, and fitted a 2-site binding model for the sigma-1 receptor. We propose this two-site binding can be used to biochemically define a sigma-1 receptor antagonist. Bis(2-ethylhexyl)ammonium and triisopentylammonium were able to inhibit the growth of tumours in vivo. Cheap, simple ammonium salts act as sigma-1 receptor agonists and antagonists in vivo and require further investigation. The sigma opioid receptor was proposed as a novel fourth opioid receptor in 1976 to account for the behavioural effects of N-allylnormetazocine (SKF-10,047) which could not be accounted for by the μ (morphine) receptor or κ (ketocyclazocine) receptor 1. Rather than causing analgesia, as with morphine, benzomorphans such as SKF-10,047 and pentazocine cause psychotomimesis. Martin proposed that SKF-10,047 was acting as a sigma opioid receptor agonist, in order to cause the psychological and behavioural effects which were observed 1. It is now recognized that there are two sigma receptors: The sigma-1 receptor consists of a 223 amino acid long protein, which shares no homology with any other known mammalian protein 2. X-ray crystallography analysis of the sigma-1 receptor has revealed a trimeric structure, with each receptor in the trimer having a single transmembrane domain anchoring it to the cytosolic side of the endoplasmic reticulum 3. N,N-dimethyltryptamine may be the endogenous sigma-1 receptor ligand despite having low affinity for the sigma-1 receptor 4. TMEM97 has now been proposed to be the unrelated "sigma-2 binding site" 5. The sigma-1 receptor has been linked with many diverse disease states and conditions. Sigma-1 receptor agonists appear to remedy symptoms of many mental conditions including depression, Alzheimer's and drug